Renal function and incidence of chronic kidney disease in HIV patients: A Danish cohort study

Abstract Background: Impaired renal function is of major concern in human immunodeficiency virus (HIV)-infected patients. Methods: We used a mixed effects linear regression model to determine estimated glomerular filtration rates (eGFRs) in a population-based cohort of incident Danish HIV patients a...

Full description

Saved in:
Bibliographic Details
Published in:Scandinavian journal of infectious diseases Vol. 44; no. 9; pp. 689 - 696
Main Authors: Rasch, Magnus G., Engsig, Frederik N., Feldt-Rasmussen, Bo, Kirk, Ole, Kronborg, Gitte, Pedersen, Court, Gerstoft, Jan, Obel, Niels
Format: Journal Article
Language:English
Published: England Informa Healthcare 01.09.2012
Taylor & Francis
Subjects:
Adenine - adverse effects
Adenine - analogs & derivatives
Adenine - therapeutic use
Adult
Anti-HIV Agents - adverse effects
Anti-HIV Agents - therapeutic use
Antiretroviral Therapy, Highly Active
atazanavir
Atazanavir Sulfate
Chronic kidney disease
Cohort Studies
Denmark - epidemiology
Female
Glomerular Filtration Rate - drug effects
HIV
HIV Infections - drug therapy
HIV Infections - epidemiology
HIV Infections - physiopathology
Humans
Incidence
Kidney - drug effects
Kidney - physiopathology
Linear Models
Male
Middle Aged
Oligopeptides - adverse effects
Oligopeptides - therapeutic use
Organophosphonates - adverse effects
Organophosphonates - therapeutic use
Pyridines - adverse effects
Pyridines - therapeutic use
renal function
Renal Insufficiency, Chronic - epidemiology
Renal Insufficiency, Chronic - virology
Tenofovir
Denmark
ISSN:0036-5548, 1651-1980, 1651-1980
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Abstract Background: Impaired renal function is of major concern in human immunodeficiency virus (HIV)-infected patients. Methods: We used a mixed effects linear regression model to determine estimated glomerular filtration rates (eGFRs) in a population-based cohort of incident Danish HIV patients and stratified on baseline eGFR (eGFRB) < 90 and ≥ 90 ml/min per 1.73 m2. Incidence rate ratios (IRRs) for chronic kidney disease (CKD) - 2 consecutive eGFR values < 60 ml/min per 1.73 m2 measured > 3 months apart - were estimated (time-updated Cox-regression model). Results: The effect of time with HIV on eGFR was small in both strata (− 0.09 (95% confidence interval (CI) − 0.27, 0.09) and − 0.46 (95% CI − 0.64, − 0.27) ml/min per 1.73 m2 per y). Treatment with tenofovir and indinavir was associated with lower eGFR in both strata: tenofovir − 2.00 (95% CI − 3.45, − 0.56) and − 1.94 (95% CI − 3.43, − 0.44) ml/min per 1.73 m2 and indinavir − 2.14 (95% CI − 3.63, − 0.64) and − 3.29 (95% CI − 5.25, − 1.32) ml/min per 1.73 m2. Nevirapine, atazanavir, and the combination of tenofovir and atazanavir were associated with lower eGFR in patients with eGFRB < 90 ml/min per 1.73 m2. Highly active antiretroviral therapy (HAART) and exposure to tenofovir and atazanavir in combination were associated with CKD in patients with eGFRB < 90 ml/min per 1.73 m2 (adjusted IRRs 6.08 (95% CI 2.76-13.41) and 26.75 (95% CI 9.54-75.05)). Conclusion: Tenofovir and indinavir reduce eGFR, while time with HIV only has a modest effect on this parameter. Low eGFRB is associated with an increased risk of CKD, especially when receiving HAART regimens containing the combination tenofovir/atazanavir.
AbstractList Impaired renal function is of major concern in human immunodeficiency virus (HIV)-infected patients.BACKGROUNDImpaired renal function is of major concern in human immunodeficiency virus (HIV)-infected patients.We used a mixed effects linear regression model to determine estimated glomerular filtration rates (eGFRs) in a population-based cohort of incident Danish HIV patients and stratified on baseline eGFR (eGFR(B)) < 90 and ≥ 90 ml/min per 1.73 m(2). Incidence rate ratios (IRRs) for chronic kidney disease (CKD) - 2 consecutive eGFR values < 60 ml/min per 1.73 m(2) measured > 3 months apart - were estimated (time-updated Cox-regression model).METHODSWe used a mixed effects linear regression model to determine estimated glomerular filtration rates (eGFRs) in a population-based cohort of incident Danish HIV patients and stratified on baseline eGFR (eGFR(B)) < 90 and ≥ 90 ml/min per 1.73 m(2). Incidence rate ratios (IRRs) for chronic kidney disease (CKD) - 2 consecutive eGFR values < 60 ml/min per 1.73 m(2) measured > 3 months apart - were estimated (time-updated Cox-regression model).The effect of time with HIV on eGFR was small in both strata (- 0.09 (95% confidence interval (CI) - 0.27, 0.09) and - 0.46 (95% CI - 0.64, - 0.27) ml/min per 1.73 m(2) per y). Treatment with tenofovir and indinavir was associated with lower eGFR in both strata: tenofovir - 2.00 (95% CI - 3.45, - 0.56) and - 1.94 (95% CI - 3.43, - 0.44) ml/min per 1.73 m(2) and indinavir - 2.14 (95% CI - 3.63, - 0.64) and - 3.29 (95% CI - 5.25, - 1.32) ml/min per 1.73 m(2). Nevirapine, atazanavir, and the combination of tenofovir and atazanavir were associated with lower eGFR in patients with eGFR(B) < 90 ml/min per 1.73 m(2). Highly active antiretroviral therapy (HAART) and exposure to tenofovir and atazanavir in combination were associated with CKD in patients with eGFR(B) < 90 ml/min per 1.73 m(2) (adjusted IRRs 6.08 (95% CI 2.76-13.41) and 26.75 (95% CI 9.54-75.05)).RESULTSThe effect of time with HIV on eGFR was small in both strata (- 0.09 (95% confidence interval (CI) - 0.27, 0.09) and - 0.46 (95% CI - 0.64, - 0.27) ml/min per 1.73 m(2) per y). Treatment with tenofovir and indinavir was associated with lower eGFR in both strata: tenofovir - 2.00 (95% CI - 3.45, - 0.56) and - 1.94 (95% CI - 3.43, - 0.44) ml/min per 1.73 m(2) and indinavir - 2.14 (95% CI - 3.63, - 0.64) and - 3.29 (95% CI - 5.25, - 1.32) ml/min per 1.73 m(2). Nevirapine, atazanavir, and the combination of tenofovir and atazanavir were associated with lower eGFR in patients with eGFR(B) < 90 ml/min per 1.73 m(2). Highly active antiretroviral therapy (HAART) and exposure to tenofovir and atazanavir in combination were associated with CKD in patients with eGFR(B) < 90 ml/min per 1.73 m(2) (adjusted IRRs 6.08 (95% CI 2.76-13.41) and 26.75 (95% CI 9.54-75.05)).Tenofovir and indinavir reduce eGFR, while time with HIV only has a modest effect on this parameter. Low eGFR(B) is associated with an increased risk of CKD, especially when receiving HAART regimens containing the combination tenofovir/atazanavir.CONCLUSIONTenofovir and indinavir reduce eGFR, while time with HIV only has a modest effect on this parameter. Low eGFR(B) is associated with an increased risk of CKD, especially when receiving HAART regimens containing the combination tenofovir/atazanavir.
Impaired renal function is of major concern in human immunodeficiency virus (HIV)-infected patients. We used a mixed effects linear regression model to determine estimated glomerular filtration rates (eGFRs) in a population-based cohort of incident Danish HIV patients and stratified on baseline eGFR (eGFR(B)) < 90 and ≥ 90 ml/min per 1.73 m(2). Incidence rate ratios (IRRs) for chronic kidney disease (CKD) - 2 consecutive eGFR values < 60 ml/min per 1.73 m(2) measured > 3 months apart - were estimated (time-updated Cox-regression model). The effect of time with HIV on eGFR was small in both strata (- 0.09 (95% confidence interval (CI) - 0.27, 0.09) and - 0.46 (95% CI - 0.64, - 0.27) ml/min per 1.73 m(2) per y). Treatment with tenofovir and indinavir was associated with lower eGFR in both strata: tenofovir - 2.00 (95% CI - 3.45, - 0.56) and - 1.94 (95% CI - 3.43, - 0.44) ml/min per 1.73 m(2) and indinavir - 2.14 (95% CI - 3.63, - 0.64) and - 3.29 (95% CI - 5.25, - 1.32) ml/min per 1.73 m(2). Nevirapine, atazanavir, and the combination of tenofovir and atazanavir were associated with lower eGFR in patients with eGFR(B) < 90 ml/min per 1.73 m(2). Highly active antiretroviral therapy (HAART) and exposure to tenofovir and atazanavir in combination were associated with CKD in patients with eGFR(B) < 90 ml/min per 1.73 m(2) (adjusted IRRs 6.08 (95% CI 2.76-13.41) and 26.75 (95% CI 9.54-75.05)). Tenofovir and indinavir reduce eGFR, while time with HIV only has a modest effect on this parameter. Low eGFR(B) is associated with an increased risk of CKD, especially when receiving HAART regimens containing the combination tenofovir/atazanavir.
Abstract Background: Impaired renal function is of major concern in human immunodeficiency virus (HIV)-infected patients. Methods: We used a mixed effects linear regression model to determine estimated glomerular filtration rates (eGFRs) in a population-based cohort of incident Danish HIV patients and stratified on baseline eGFR (eGFRB) < 90 and ≥ 90 ml/min per 1.73 m2. Incidence rate ratios (IRRs) for chronic kidney disease (CKD) - 2 consecutive eGFR values < 60 ml/min per 1.73 m2 measured > 3 months apart - were estimated (time-updated Cox-regression model). Results: The effect of time with HIV on eGFR was small in both strata (− 0.09 (95% confidence interval (CI) − 0.27, 0.09) and − 0.46 (95% CI − 0.64, − 0.27) ml/min per 1.73 m2 per y). Treatment with tenofovir and indinavir was associated with lower eGFR in both strata: tenofovir − 2.00 (95% CI − 3.45, − 0.56) and − 1.94 (95% CI − 3.43, − 0.44) ml/min per 1.73 m2 and indinavir − 2.14 (95% CI − 3.63, − 0.64) and − 3.29 (95% CI − 5.25, − 1.32) ml/min per 1.73 m2. Nevirapine, atazanavir, and the combination of tenofovir and atazanavir were associated with lower eGFR in patients with eGFRB < 90 ml/min per 1.73 m2. Highly active antiretroviral therapy (HAART) and exposure to tenofovir and atazanavir in combination were associated with CKD in patients with eGFRB < 90 ml/min per 1.73 m2 (adjusted IRRs 6.08 (95% CI 2.76-13.41) and 26.75 (95% CI 9.54-75.05)). Conclusion: Tenofovir and indinavir reduce eGFR, while time with HIV only has a modest effect on this parameter. Low eGFRB is associated with an increased risk of CKD, especially when receiving HAART regimens containing the combination tenofovir/atazanavir.
Background: Impaired renal function is of major concern in human immunodeficiency virus (HIV)-infected patients. Methods: We used a mixed effects linear regression model to determine estimated glomerular filtration rates (eGFRs) in a population-based cohort of incident Danish HIV patients and stratified on baseline eGFR (eGFR B ) < 90 and ≥ 90 ml/min per 1.73 m 2 . Incidence rate ratios (IRRs) for chronic kidney disease (CKD) - 2 consecutive eGFR values < 60 ml/min per 1.73 m 2 measured > 3 months apart - were estimated (time-updated Cox-regression model). Results: The effect of time with HIV on eGFR was small in both strata (− 0.09 (95% confidence interval (CI) − 0.27, 0.09) and − 0.46 (95% CI − 0.64, − 0.27) ml/min per 1.73 m 2 per y). Treatment with tenofovir and indinavir was associated with lower eGFR in both strata: tenofovir − 2.00 (95% CI − 3.45, − 0.56) and − 1.94 (95% CI − 3.43, − 0.44) ml/min per 1.73 m 2 and indinavir − 2.14 (95% CI − 3.63, − 0.64) and − 3.29 (95% CI − 5.25, − 1.32) ml/min per 1.73 m 2 . Nevirapine, atazanavir, and the combination of tenofovir and atazanavir were associated with lower eGFR in patients with eGFR B < 90 ml/min per 1.73 m 2 . Highly active antiretroviral therapy (HAART) and exposure to tenofovir and atazanavir in combination were associated with CKD in patients with eGFR B < 90 ml/min per 1.73 m 2 (adjusted IRRs 6.08 (95% CI 2.76-13.41) and 26.75 (95% CI 9.54-75.05)). Conclusion: Tenofovir and indinavir reduce eGFR, while time with HIV only has a modest effect on this parameter. Low eGFR B is associated with an increased risk of CKD, especially when receiving HAART regimens containing the combination tenofovir/atazanavir.
Author Rasch, Magnus G.
Engsig, Frederik N.
Feldt-Rasmussen, Bo
Kronborg, Gitte
Pedersen, Court
Gerstoft, Jan
Obel, Niels
Kirk, Ole
Author_xml – sequence: 1
  givenname: Magnus G.
  surname: Rasch
  fullname: Rasch, Magnus G.
  email: magnus.rasch@gmail.com, magnus.rasch@gmail.com
  organization: Department of Infectious Diseases, Copenhagen University Hospital
– sequence: 2
  givenname: Frederik N.
  surname: Engsig
  fullname: Engsig, Frederik N.
  email: magnus.rasch@gmail.com, magnus.rasch@gmail.com
  organization: Department of Infectious Diseases, Copenhagen University Hospital
– sequence: 3
  givenname: Bo
  surname: Feldt-Rasmussen
  fullname: Feldt-Rasmussen, Bo
  email: magnus.rasch@gmail.com, magnus.rasch@gmail.com
  organization: Department of Nephrology, Copenhagen University Hospital
– sequence: 4
  givenname: Ole
  surname: Kirk
  fullname: Kirk, Ole
  email: magnus.rasch@gmail.com, magnus.rasch@gmail.com
  organization: Department of Infectious Diseases, Copenhagen University Hospital
– sequence: 5
  givenname: Gitte
  surname: Kronborg
  fullname: Kronborg, Gitte
  email: magnus.rasch@gmail.com, magnus.rasch@gmail.com
  organization: Department of Infectious Diseases, Copenhagen University Hospital
– sequence: 6
  givenname: Court
  surname: Pedersen
  fullname: Pedersen, Court
  email: magnus.rasch@gmail.com, magnus.rasch@gmail.com
  organization: Department of Infectious Diseases, Odense University Hospital
– sequence: 7
  givenname: Jan
  surname: Gerstoft
  fullname: Gerstoft, Jan
  email: magnus.rasch@gmail.com, magnus.rasch@gmail.com
  organization: Department of Infectious Diseases, Copenhagen University Hospital
– sequence: 8
  givenname: Niels
  surname: Obel
  fullname: Obel, Niels
  email: magnus.rasch@gmail.com, magnus.rasch@gmail.com
  organization: Department of Infectious Diseases, Copenhagen University Hospital
BackLink https://www.ncbi.nlm.nih.gov/pubmed/22680981$$D View this record in MEDLINE/PubMed
BookMark eNqFkU9LHDEYh0Ox1NX2G5SSYy-zvsnMZBIPLWJbFQRBpLcSMvnDxM4m2ySD7LfvDKsFPdhTLs_zIzzvEToIMViEPhJY1wTECUDN2rbhawqErllXdzW8QSvCWlIRweEArRakWphDdJTzPQA0rIZ36JBSxkFwskK_bm1QI3ZT0MXHgFUw2AftjQ3a4uiwHlIMXuPf3gS7w8Znq7KdGXx59RNvVfE2lHyKz_A3FXwesI5DTAXnMpnde_TWqTHbD4_vMbr78f3u_LK6vrm4Oj-7rnRDeKlYC7QB0bWC906xtut60uq2JoJR46ijthMOOuYIp8B7LnTLed8YK3rGjauP0ef97DbFP5PNRW581nYcVbBxypJA3RAhQNAZ_fSITv3GGrlNfqPSTj4VmYFmD-gUc07W_UMIyCW8fAovl_ByH37WTl9o2he1JC1J-fF_8te97IOLaaMeYhqNLGo3xuSSms-RF_vVhS_PFgarxjJolay8j1OaT5xf_8JfatWszg
CitedBy_id crossref_primary_10_1007_s40121_014_0056_4
crossref_primary_10_1177_0956462420942020
crossref_primary_10_1371_journal_pone_0135462
crossref_primary_10_1007_s10157_013_0817_5
crossref_primary_10_1093_ndt_gft289
crossref_primary_10_1097_QAD_0000000000000736
crossref_primary_10_1097_QAD_0000000000000103
crossref_primary_10_4102_sajhivmed_v21i1_1133
crossref_primary_10_1002_pds_5125
crossref_primary_10_1186_s12879_019_4184_z
crossref_primary_10_1002_pds_4657
crossref_primary_10_1177_0956462419848962
crossref_primary_10_1016_j_bjid_2018_05_001
crossref_primary_10_1186_s12879_022_07739_y
crossref_primary_10_1007_s11904_014_0209_9
crossref_primary_10_1038_s43856_024_00453_7
crossref_primary_10_1136_bmjopen_2024_090345
crossref_primary_10_1097_MD_0000000000003780
crossref_primary_10_1186_s12882_022_02721_x
crossref_primary_10_1186_s12882_020_01754_4
crossref_primary_10_1093_ckj_sfv015
crossref_primary_10_1111_hiv_12249
crossref_primary_10_1111_hiv_12426
crossref_primary_10_4102_sajhivmed_v26i1_1640
crossref_primary_10_1097_QAD_0000000000001041
crossref_primary_10_3389_fmed_2024_1455688
Cites_doi 10.1345/aph.18004
10.1097/QAD.0b013e328339fe53
10.1038/sj.ki.5001641
10.1086/503566
10.7326/0003-4819-141-12-200412210-00009
10.1111/j.1464-5491.1985.tb00586.x
10.1086/524061
10.1097/00002030-199818000-00003
10.1038/ki.2010.318
10.1093/ndt/gfp534
10.1097/QAD.0b013e3282f17503
10.1161/CIRCULATIONAHA.110.940932
10.5858/2005-129-297-CMSOTA
10.1038/sj.clpt.6100269
10.7326/0003-4819-154-7-201104050-00316
10.1016/S0272-6386(04)01093-5
10.1542/peds.111.6.1416
10.7326/0003-4819-139-3-200308050-00019
10.7326/0003-4819-145-4-200608150-00004
10.1111/j.1468-1293.2011.00941.x
10.1007/s00125-010-1794-9
10.1111/j.1748-1716.2010.02147.x
10.1097/QAD.0b013e3280f774ee
10.1097/QAD.0b013e3282f4706d
10.1097/01.qai.0000179459.31562.16
10.1590/S0100-879X2006000800009
10.1186/1742-6405-7-37
10.1517/14740331003627458
10.1097/01.qai.0000228790.40235.0c
10.1080/00365540510031692
10.1007/s00428-007-0418-3
10.1086/587994
10.2337/dc10-0767
ContentType Journal Article
Copyright 2012 Informa Healthcare 2012
Copyright_xml – notice: 2012 Informa Healthcare 2012
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.3109/00365548.2012.673730
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1651-1980
EndPage 696
ExternalDocumentID 22680981
10_3109_00365548_2012_673730
673730
Genre Research Article
Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Denmark
GeographicLocations_xml – name: Denmark
GroupedDBID ---
.GJ
00X
08R
0BK
123
34G
36B
39C
4.4
53G
5RE
5VS
AAJNR
AALIY
AALUX
AAMIU
AAPUL
AAPXX
AAQQT
AAQRR
AAWTL
ABBKH
ABDBF
ABLJU
ABPTK
ABUPF
ABWCV
ABZEW
ACENM
ACFUF
ACGEJ
ACGFO
ACGFS
ACKZS
ACLSK
ADCVX
ADFCX
ADFOM
ADFZZ
ADXPE
AEIIZ
AEYQI
AFFNX
AFKVX
AFLEI
AFOSN
AFWLO
AGDLA
AGFJD
AGRBW
AGYJP
AIJEM
AIRBT
AJVHN
AJWEG
AKBVH
ALIIL
ALMA_UNASSIGNED_HOLDINGS
ALQZU
AMDAE
AWYRJ
BABNJ
BLEHA
BOHLJ
BRMBE
CAG
CCCUG
COF
CS3
CYYVM
CZDIS
DKSSO
DRXRE
DU5
DWTOO
EAP
EAS
EBC
EBD
EBS
EHN
EJD
EMB
EMK
EMOBN
ENC
ENX
EPL
EPT
ESX
F5P
H13
HZ~
JENTW
KRBQP
KSSTO
KWAYT
KYCEM
L7B
M44
M4Z
OVD
P2P
QQXMO
Q~Q
RNANH
RVRKI
SV3
TEORI
TFL
TFW
TUS
UDS
UEQFS
V1S
ZGI
ZXP
~1N
AAGDL
ABJNI
ABLIJ
ABWVI
ABXYU
ACIEZ
ACUHS
AFRVT
ALYBC
AQTUD
TASJS
TBQAZ
TDBHL
TERGH
TUROJ
AAJKZ
AAORF
AAYXX
ACOPL
CITATION
ADYSH
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c418t-65024097598bfa6577b15c531962df2f2e79f076f18208b89c588b4de9b68df3
IEDL.DBID TFW
ISICitedReferencesCount 32
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000307996500008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0036-5548
1651-1980
IngestDate Fri Sep 05 05:43:42 EDT 2025
Mon Jul 21 06:00:54 EDT 2025
Sat Nov 29 04:03:50 EST 2025
Tue Nov 18 22:28:42 EST 2025
Mon Oct 20 23:45:15 EDT 2025
Wed Jun 21 01:44:37 EDT 2023
IsPeerReviewed false
IsScholarly false
Issue 9
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c418t-65024097598bfa6577b15c531962df2f2e79f076f18208b89c588b4de9b68df3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 22680981
PQID 1034199092
PQPubID 23479
PageCount 8
ParticipantIDs informahealthcare_journals_10_3109_00365548_2012_673730
pubmed_primary_22680981
proquest_miscellaneous_1034199092
informaworld_taylorfrancis_310_3109_00365548_2012_673730
crossref_primary_10_3109_00365548_2012_673730
crossref_citationtrail_10_3109_00365548_2012_673730
PublicationCentury 2000
PublicationDate 20120900
9/1/2012
2012-09-00
2012-Sep
20120901
PublicationDateYYYYMMDD 2012-09-01
PublicationDate_xml – month: 09
  year: 2012
  text: 20120900
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Scandinavian journal of infectious diseases
PublicationTitleAlternate Scand J Infect Dis
PublicationYear 2012
Publisher Informa Healthcare
Taylor & Francis
Publisher_xml – name: Informa Healthcare
– name: Taylor & Francis
References Daar ES (CIT0009) 2011; 154
Boubaker K (CIT0026) 1998; 12
CIT0010
CIT0032
Rodriguez-Nvoa S (CIT0005) 2010; 9
Mocroft A (CIT0017) 2010; 24
Izzedine H (CIT0029) 2007; 21
Manosuthi W (CIT0027) 2010; 7
Hogg R (CIT0013) 2003; 111
Cirillo M (CIT0024) 2006; 70
Kalayjian R (CIT0018) 2008; 22
Rling J (CIT0003) 2006; 42
CIT0016
Vrouenraets SM (CIT0031) 2011; 12
CIT0015
Lohse N (CIT0002) 2005; 37
Jerums G (CIT0022) 2010; 53
Schmid S (CIT0008) 2007; 450
Christiansen JS (CIT0019) 1985; 2
CIT0020
Hanratty R (CIT0025) 2010; 25
Kimmel P (CIT0011) 2003; 139
Jiang B (CIT0033) 2006; 42
Perticone F (CIT0023) 2010; 122
Lucas G (CIT0028) 2008; 197
Persson P (CIT0021) 2010; 200
Eira M (CIT0007) 2006; 39
Levey A (CIT0012) 2006; 145
Miller WG (CIT0014) 2005; 129
Marroni M (CIT0030) 1998; 32
Brewster U (CIT0006) 2004; 44
CIT0004
Crum N (CIT0001) 2006; 41
References_xml – volume: 32
  start-page: 843
  year: 1998
  ident: CIT0030
  publication-title: Ann Pharmacother
  doi: 10.1345/aph.18004
– volume: 24
  start-page: 1667
  year: 2010
  ident: CIT0017
  publication-title: AIDS
  doi: 10.1097/QAD.0b013e328339fe53
– volume: 70
  start-page: 800
  year: 2006
  ident: CIT0024
  publication-title: Kidney Int
  doi: 10.1038/sj.ki.5001641
– volume: 42
  start-page: 1488
  year: 2006
  ident: CIT0003
  publication-title: Clin Infect Dis
  doi: 10.1086/503566
– ident: CIT0015
  doi: 10.7326/0003-4819-141-12-200412210-00009
– volume: 2
  start-page: 235
  year: 1985
  ident: CIT0019
  publication-title: Diabet Med
  doi: 10.1111/j.1464-5491.1985.tb00586.x
– ident: CIT0010
  doi: 10.1086/524061
– volume: 12
  start-page: F249
  year: 1998
  ident: CIT0026
  publication-title: AIDS
  doi: 10.1097/00002030-199818000-00003
– ident: CIT0004
  doi: 10.1038/ki.2010.318
– volume: 25
  start-page: 801
  year: 2010
  ident: CIT0025
  publication-title: Nephrol Dial Transplant
  doi: 10.1093/ndt/gfp534
– volume: 21
  start-page: 2357
  year: 2007
  ident: CIT0029
  publication-title: AIDS
  doi: 10.1097/QAD.0b013e3282f17503
– volume: 122
  start-page: 379
  year: 2010
  ident: CIT0023
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.110.940932
– volume: 129
  start-page: 297
  year: 2005
  ident: CIT0014
  publication-title: Arch Pathol Lab Med
  doi: 10.5858/2005-129-297-CMSOTA
– ident: CIT0032
  doi: 10.1038/sj.clpt.6100269
– volume: 154
  start-page: 445
  year: 2011
  ident: CIT0009
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-154-7-201104050-00316
– volume: 44
  start-page: e81
  year: 2004
  ident: CIT0006
  publication-title: Am J Kidney Dis
  doi: 10.1016/S0272-6386(04)01093-5
– volume: 111
  start-page: 1416
  year: 2003
  ident: CIT0013
  publication-title: Pediatrics
  doi: 10.1542/peds.111.6.1416
– volume: 139
  start-page: 214
  year: 2003
  ident: CIT0011
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-139-3-200308050-00019
– volume: 145
  start-page: 247
  year: 2006
  ident: CIT0012
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-145-4-200608150-00004
– volume: 12
  start-page: 620
  year: 2011
  ident: CIT0031
  publication-title: HIV Med
  doi: 10.1111/j.1468-1293.2011.00941.x
– volume: 53
  start-page: 2093
  year: 2010
  ident: CIT0022
  publication-title: Diabetologia
  doi: 10.1007/s00125-010-1794-9
– volume: 200
  start-page: 3
  year: 2010
  ident: CIT0021
  publication-title: Acta Physiol (Oxf.)
  doi: 10.1111/j.1748-1716.2010.02147.x
– ident: CIT0016
  doi: 10.1097/QAD.0b013e3280f774ee
– volume: 22
  start-page: 481
  year: 2008
  ident: CIT0018
  publication-title: AIDS
  doi: 10.1097/QAD.0b013e3282f4706d
– volume: 41
  start-page: 194
  year: 2006
  ident: CIT0001
  publication-title: J Acquir Immune Defic Syndr
  doi: 10.1097/01.qai.0000179459.31562.16
– volume: 39
  start-page: 1065
  year: 2006
  ident: CIT0007
  publication-title: Braz J Med Biol Res
  doi: 10.1590/S0100-879X2006000800009
– volume: 7
  start-page: 37
  year: 2010
  ident: CIT0027
  publication-title: AIDS Res Ther
  doi: 10.1186/1742-6405-7-37
– volume: 9
  start-page: 545
  year: 2010
  ident: CIT0005
  publication-title: Expert Opin Drug Saf
  doi: 10.1517/14740331003627458
– volume: 42
  start-page: 391
  year: 2006
  ident: CIT0033
  publication-title: J Acquir Immune Defic Syndr
  doi: 10.1097/01.qai.0000228790.40235.0c
– volume: 37
  start-page: 338
  year: 2005
  ident: CIT0002
  publication-title: Scand J Infect Dis
  doi: 10.1080/00365540510031692
– volume: 450
  start-page: 665
  year: 2007
  ident: CIT0008
  publication-title: Virchows Arch
  doi: 10.1007/s00428-007-0418-3
– volume: 197
  start-page: 1548
  year: 2008
  ident: CIT0028
  publication-title: J Infect Dis
  doi: 10.1086/587994
– ident: CIT0020
  doi: 10.2337/dc10-0767
SSID ssj0004630
Score 1.6292183
Snippet Abstract Background: Impaired renal function is of major concern in human immunodeficiency virus (HIV)-infected patients. Methods: We used a mixed effects...
Background: Impaired renal function is of major concern in human immunodeficiency virus (HIV)-infected patients. Methods: We used a mixed effects linear...
Impaired renal function is of major concern in human immunodeficiency virus (HIV)-infected patients. We used a mixed effects linear regression model to...
Impaired renal function is of major concern in human immunodeficiency virus (HIV)-infected patients.BACKGROUNDImpaired renal function is of major concern in...
SourceID proquest
pubmed
crossref
informaworld
informahealthcare
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 689
SubjectTerms Adenine - adverse effects
Adenine - analogs & derivatives
Adenine - therapeutic use
Adult
Anti-HIV Agents - adverse effects
Anti-HIV Agents - therapeutic use
Antiretroviral Therapy, Highly Active
atazanavir
Atazanavir Sulfate
Chronic kidney disease
Cohort Studies
Denmark - epidemiology
Female
Glomerular Filtration Rate - drug effects
HIV
HIV Infections - drug therapy
HIV Infections - epidemiology
HIV Infections - physiopathology
Humans
Incidence
Kidney - drug effects
Kidney - physiopathology
Linear Models
Male
Middle Aged
Oligopeptides - adverse effects
Oligopeptides - therapeutic use
Organophosphonates - adverse effects
Organophosphonates - therapeutic use
Pyridines - adverse effects
Pyridines - therapeutic use
renal function
Renal Insufficiency, Chronic - epidemiology
Renal Insufficiency, Chronic - virology
Tenofovir
Title Renal function and incidence of chronic kidney disease in HIV patients: A Danish cohort study
URI https://www.tandfonline.com/doi/abs/10.3109/00365548.2012.673730
https://www.ncbi.nlm.nih.gov/pubmed/22680981
https://www.proquest.com/docview/1034199092
Volume 44
WOSCitedRecordID wos000307996500008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAWR
  databaseName: Taylor & Francis Online Journals
  customDbUrl:
  eissn: 1651-1980
  dateEnd: 20141231
  omitProxy: false
  ssIdentifier: ssj0004630
  issn: 0036-5548
  databaseCode: TFW
  dateStart: 19690501
  isFulltext: true
  titleUrlDefault: https://www.tandfonline.com
  providerName: Taylor & Francis
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS8MwEA86RHzR-T0_RgRfK236lfg2xDFBh8iYe5HSpAkbSidbJ_jfm0vaMZUp6GNpriHJXe-Su_x-CJ37PFM0FNQJQkacQGaek2Z6QYRilKaSCNfwkPVv426XDgbsfuEWP5RVwh5aWaAI868G4065YSABHEvgH4u0FzSFWeQCiFZ82LRrzw8UBr3248LFSN-tUHdBwt6dW_qRT76pXiKXDud1WF_QTJfHpMY3tbf-P6o62izjUtyyirSNVmS-g9bvysz7Lnp6kPAe3CAsJdbdYDimN5SkeKywsCi7-HmU5fIdl4kf3QZ3bvq4hG-dXuIWhlvt0yEGat5JgQ2-7R7qta97Vx2npGZwRODRwtFxHQGkrJBRrtIojGPuhcLYM8kUUUTGTLlxpAAfnnLKREgpDzLJeEQz5e-jWj7O5SHCoVLS46mvGJMB0aG-FwEmTsZjD1K4bgP51ZokooQtB_aMl0RvX2DikmriEpi4xE5cAzlzqVcL2_FL-_jbcielNU9_kaSLSpEU5qBFWVYUEPtJ9KxSoEQbNWRq0lyOZ9AhwOwxl5EGOrCaNR-Gjpepy6h39PeOj9EGPNlSuRNUKyYzeYrWxFsxmk6aaDUe0KYxpA-nUhOD
linkProvider Taylor & Francis
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3dS8MwEA-ior7o_J6fEXyttulX4puIY-IcIkN9kdCmCYrSyVoF_3tzSTamooL4nFzTJrneXe7y-yG0H-aForGgXhQz4kWyCLys0AsiFKM0k0T4hofsupN2u_T2ll26asLKlVVCDK0sUIT5V4Nyw2H0oQkxfQYEZIk2g6YyixwA00qoo_Yp7QnEQGLQa92MXY0M_SHuLojY23PfPuWDdWo47NL7USXWJzzT771SY51aC__wXQ0071xTfGz30iKakOUSmrlwyfdldHcloR0sIawm1uNgOKk3rKS4r7CwQLv48aEo5Rt2uR_dB7fPrrFDcK2O8DGGi-3VPQZ23kGNDcTtCuq1Tnsnbc-xM3giCmjtadeOAFhWzGiusiRO0zyIhVFpUiiiiEyZ8tNEAUQ8zSkTMaV5VEiWJ7RQ4SqaLPulXEc4VkoGeRYqxmREtLcfJACLU-RpAFlcv4nC4aJw4ZDLgUDjiesIBiaODyeOw8RxO3FN5I2kni1yxy_90y_rzZ1CV79I0vFdwWtz1qIsMQqI_SS6N9xBXOs1JGuyUvZfYEBA2mM-I020ZrfW6DO0y0x9RoONP7_yLppt9y46vHPWPd9Ec9BiC-e20GQ9eJHbaFq81g_VYMeo0ztKmBZY
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ZS8QwEA6iIr54H-sZwddqm16Jb6IuirossqgvEtocrChd2VbBf28m6S6rsgr6nEzTZmY6M8nMNwjth7nUNBbUi2JGvEjJwMukYYjQjNJMEeHbPmS3V2mrRe_vWXukih_SKiGG1g4owv6rQblfpD60EabPoP9YYqygTcwiB9BoJTRB-1TiG-ffSHSneTdSGRn6A9hdIHHFc2Of8sk4LdTQpd1hItYXONPxTqk1Ts35_3_WApqrHVN87CRpEU2oYgnNXNdX78vo4UbBONhB4CU2y2A4p7c9SXFPY-FgdvHToyzUO65vfswcfH5xi2v81vIIH2Moay-7GHrz9itsAW5XUKd51jk59-reDJ6IAlp5xrEjAJUVM5rrLInTNA9iYRWaSE00USnTfppoAIinOWUipjSPpGJ5QqUOV9Fk0SvUOsKx1irIs1AzpiJifP0gAVAcmacB3OH6DRQOeMJFjVsO7TOeuYlfYOP4YOM4bBx3G9dA3pDqxeF2_DI__cZuXqtz-QslHRUKXtmTFu3aogDZT6R7AwHiRqvhqiYrVO8VFgScPeYz0kBrTrKGn2EcZuozGmz8-ZV30Uz7tMmvLlqXm2gWBlzW3BaarPqvahtNi7fqsezvWGX6APUrFRA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Renal+function+and+incidence+of+chronic+kidney+disease+in+HIV+patients%3A+A+Danish+cohort+study&rft.jtitle=Scandinavian+journal+of+infectious+diseases&rft.au=Rasch%2C+Magnus+G.&rft.au=Engsig%2C+Frederik+N.&rft.au=Feldt-Rasmussen%2C+Bo&rft.au=Kirk%2C+Ole&rft.date=2012-09-01&rft.issn=0036-5548&rft.eissn=1651-1980&rft.volume=44&rft.issue=9&rft.spage=689&rft.epage=696&rft_id=info:doi/10.3109%2F00365548.2012.673730&rft.externalDBID=n%2Fa&rft.externalDocID=10_3109_00365548_2012_673730
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0036-5548&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0036-5548&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0036-5548&client=summon